Bioventus Enters Material Definitive Agreement; Details Undisclosed

Ticker: BVS · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1665988

Complexity: simple

Sentiment: neutral

Topics: material-agreement, corporate-action, undisclosed-terms

TL;DR

**Bioventus signed a big deal, but they're not telling us what it is yet.**

AI Summary

Bioventus Inc. filed an 8-K on January 19, 2024, reporting an "Entry into a Material Definitive Agreement" on January 18, 2024. While the filing indicates a significant new agreement, it does not disclose the specific details, parties, or financial terms of this agreement. This matters to investors because a material definitive agreement can significantly impact the company's future revenue, expenses, and strategic direction, but without details, the impact on Bioventus's stock (BVS) remains uncertain.

Why It Matters

This filing signals a potentially significant business development for Bioventus, but the lack of specific details means investors cannot yet assess its financial implications or strategic value.

Risk Assessment

Risk Level: medium — The risk is medium because a material agreement could be very positive or negative, and the lack of transparency creates uncertainty for investors.

Analyst Insight

A smart investor would await further disclosures from Bioventus Inc. detailing the terms and implications of this material definitive agreement before making any investment decisions, as the current filing lacks critical information.

Key Players & Entities

FAQ

What was the specific event reported in this 8-K filing by Bioventus Inc.?

Bioventus Inc. reported the "Entry into a Material Definitive Agreement" as the earliest event on January 18, 2024, under Item 1.01 of the 8-K filing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 18, 2024, which is the date Bioventus Inc. entered into the material definitive agreement.

What is the trading symbol and the exchange where Bioventus Inc.'s Class A Common Stock is registered?

Bioventus Inc.'s Class A Common Stock, with a $0.001 par value per share, trades under the symbol BVS and is registered on The Nasdaq Global Select Market.

What information is notably absent from this 8-K filing regarding the material definitive agreement?

This 8-K filing notably omits specific details about the material definitive agreement, such as the parties involved, the nature of the agreement, or any financial terms, making it impossible to assess its impact.

What is Bioventus Inc.'s business address and phone number as listed in the filing?

Bioventus Inc.'s business address is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) 474-6700.

Filing Stats: 1,161 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-01-19 08:27:00

Key Financial Figures

Filing Documents

01

Item 1.01. Entry into a Material Definitive Agreement.. On January 18, 2024 (the "Closing Date"), Bioventus LLC ("Bioventus LLC"), a Delaware limited liability company and subsidiary of Bioventus Inc. (together with its subsidiaries, the "Company") and certain of its subsidiaries entered into an Amendment No. 5 to the Credit and Guaranty Agreement (the "Fifth Amendment") with Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institutions party thereto, which amended the Credit and Guaranty Agreement, dated as of December 6, 2019 (the "2019 Credit Agreement," and, as amended by that certain Amendment No. 1 to Credit and Guaranty Agreement, dated as of August 29, 2021, by the Second Amendment to Credit and Guaranty Agreement, dated as of October 29, 2021, by the Third Amendment to Credit and Guaranty Agreement, dated as of July 11, 2022, by the Fourth Amendment to Credit and Guaranty Agreement, dated as of March 31, 2023 and by the Fifth Amendment, the "Amended 2019 Credit Agreement"). The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC's equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. As amended by the Fifth Amendment, the financial covenant requirements include: a maximum debt leverage ratio of not greater than 5.65 to 1.00 for the testing period ending March 31, 2024, 5.00 to 1.00 for the testing period ending June 30, 2024, 4.75 to 1.00 for the testing period ending Septem

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 Amendment No. 5 to the Credit and Guaranty Agreement by and between Bioventus LLC, Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institutions party thereto. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: January 19, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing